Topical calcineurin inhibitors labeling: Putting the "box" in perspective [3]

Archives of Dermatology

Volumn 142, Issue 9, 2006, Pages 1233-1235

  Stern, Robert S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; PIMECROLIMUS; PLACEBO; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

ATOPIC DERMATITIS; CLINICAL PRACTICE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUSTRY; DRUG LABELING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; LONG TERM CARE; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK FACTOR; SKIN CARCINOMA; SYSTEMATIC REVIEW; TREATMENT INDICATION;

ADMINISTRATION, CUTANEOUS; CALCINEURIN; DERMATITIS, ATOPIC; DRUG APPROVAL; DRUG LABELING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33748764373     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.9.1233     Document Type: Letter

References (11)

1. Qureshi AA, Fischer MA. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol. 2006;142:633-637.
2. Food and Drug Administration Center for Drug Evaluation and Research. Dermatologic and Opthlamic Drugs Advisory Committee: Meeting No. 54. Rockville, Md: Food and Drug Administration; November 16, 2000. http://www.fda.gov/ohrms/ dockets/ac/00/transcripts/3659t1a.pdf. Accessed June 1, 2006.
3. Food and Drug Administration Center for Drug Evaluation and Research. Pediatric Advisory Subcommittee of the Anti-infective Drugs Advisory Committee. Rockville, Md: Food and Drug Administration; October 30, 2003. http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3999T2.htm. Accessed June 1, 2006.
4. Ashcroft D, Dimmock P, Garside R, Stein K, Williams H. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials [published online ahead of print February 24, 2005]. BMJ. 2005;330:516. doi:10.1136/bmj.38376. 439653.D3. Accessed June 1, 2006.
5. Food and Drug Administration. Pediatric Advisory Committee: Sixth Meeting. Rockville, Md: Food and Drug Administration; Food and Drug Administration; February 15, 2005. http://www.fda.gov/ohrms/dockets/ac/05/ transcripts/2005-4089T2.pdf. Accessed June 1, 2006.
6. Elidel [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; January 19, 2006. http://www.fda.gov/cder/foi/label/2006/021302s011lbl.pdf. Accessed June 1, 2006.
7. Novartis. Medication Guide: ELIDEL [ELì-ee-del] Cream 1%: (pimecrolimus). East Hanover, NJ: Novartis Pharmaceuticals Corp; January 19, 2006. http://www.fda.gov/cder/drug/infopage/elidel/lMG_20061019.pdf. Accessed June 1, 2006.
8. Astellas Pharma US Inc. Medication Guide: Protopic [pro-TOP-ik] (tacrolimus): Ointment 0.03%; Ointment 0.1%. Deerfield, Ill: Astellas Pharma US Inc; 2006. http://www.fda.gov/cder/drug/infopage/protopic/MG_20060119.pdf. Accessed June 1, 2006.
9. Protopic [package insert]. Deerfield, Ill: Astellas Pharma US Inc; 2006. http://www.fda.gov/cder/foi/label/2006/050777s012lbl.pdf. Accessed June 1, 2006.
10. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplant. Br J Dermatol. 2000;143:513-519.
11. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol. 2005;125:1020-1025.